Boston Scientific Corporation $BSX Shares Purchased by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 13.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 753,076 shares of the medical equipment provider’s stock after purchasing an additional 87,185 shares during the period. Royal London Asset Management Ltd.’s holdings in Boston Scientific were worth $32,141,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Toth Financial Advisory Corp raised its holdings in shares of Boston Scientific by 569.1% in the second quarter. Toth Financial Advisory Corp now owns 823 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 700 shares during the last quarter. Mufg Securities Americas Inc. grew its holdings in shares of Boston Scientific by 9.1% during the second quarter. Mufg Securities Americas Inc. now owns 44,767 shares of the medical equipment provider’s stock worth $1,911,000 after buying an additional 3,731 shares during the last quarter. Van ECK Associates Corp increased its position in Boston Scientific by 7.0% in the 2nd quarter. Van ECK Associates Corp now owns 94,958 shares of the medical equipment provider’s stock valued at $4,053,000 after acquiring an additional 6,185 shares during the period. Nissay Asset Management Corp Japan raised its stake in Boston Scientific by 4.5% during the 2nd quarter. Nissay Asset Management Corp Japan now owns 198,026 shares of the medical equipment provider’s stock valued at $8,452,000 after acquiring an additional 8,450 shares during the last quarter. Finally, Lombard Odier Asset Management Europe Ltd purchased a new stake in Boston Scientific during the 2nd quarter valued at approximately $2,618,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BSX has been the topic of several analyst reports. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Evercore set a $65.00 price target on shares of Boston Scientific in a research report on Monday, July 6th. Barclays lowered their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Jefferies Financial Group dropped their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Finally, Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Trading Up 0.3%

Shares of Boston Scientific stock opened at $46.82 on Friday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business has a 50 day moving average price of $46.56 and a 200 day moving average price of $56.65. The company has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 194,522 shares of company stock valued at $9,385,210 over the last quarter. Insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.